Purpose: The aim of this paper was to evaluate treatment outcomes following interventional radiotherapy (brachytherapy – BT) for nasal vestibule cancer. Material and methods: Considering histological diagnosis and staging, a multidisciplinary tumor board indicated an exclusive interventional radiotherapy for all patients. Plastic tubes were placed mainly with interstitial approach. The total dose was 44 Gy in 14 fractions, 3 Gy/fraction (except for the first and last fractions, 4 Gy), 2 fractions per day (b.i.d.), 5 days a week. Inclusion criteria for this analysis were: patients affected by squamous cell carcinoma with follow-up more than 6 months. Results: 20 patients with primary nasal vestibule cancer were treated with IRT from May 2012 to June 2019. We excluded 4 patients due to follow-up less than 6 months and 2 patients affected by basal cell carcinoma. In total, 14 consecutive previously untreated patients were considered for definitive analysis, median age was 67.5 (range, 51-83) years, median follow-up was 53 (range, 6-84) months. All patients followed the protocol except one, who received a total dose of 42 Gy in 12 fractions, 3 Gy per 6 fractions, and 4 Gy per 6 fractions. Local control at 12, 24, and 36 months was 85.7%. Overall survival at 12 months was 92.3%, at 24 months was 76.9%, and at 36 months was 69.2%. Staging system proposed by Wang was statistically significant on local control (LC), disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). Excellent cosmetic results were observed. Conclusions: This study confirms that interventional radiotherapy could be considered as a definitive treatment in nasal vestibule cancer with excellent oncological and cosmetic outcomes.

Tagliaferri, L., Carra, N., Lancellotta, V., Rizzo, D., Casa, C., Mattiucci, G., Parrilla, C., Fionda, B., Deodato, F., Cornacchione, P., Gambacorta, M. A., Paludetti, G., Valentini, V., Bussu, F., Interventional radiotherapy as exclusive treatment for primary nasal vestibule cancer: Single-institution experience, <<JOURNAL OF CONTEMPORARY BRACHYTHERAPY>>, 2020; 12 (5): 413-419. [doi:10.5114/jcb.2020.100373] [http://hdl.handle.net/10807/171559]

Interventional radiotherapy as exclusive treatment for primary nasal vestibule cancer: Single-institution experience

Tagliaferri L.;Rizzo D.;Mattiucci G.;Parrilla C.;Deodato F.;Cornacchione P.;Gambacorta M. A.;Paludetti G.;Valentini V.;Bussu F.
2020

Abstract

Purpose: The aim of this paper was to evaluate treatment outcomes following interventional radiotherapy (brachytherapy – BT) for nasal vestibule cancer. Material and methods: Considering histological diagnosis and staging, a multidisciplinary tumor board indicated an exclusive interventional radiotherapy for all patients. Plastic tubes were placed mainly with interstitial approach. The total dose was 44 Gy in 14 fractions, 3 Gy/fraction (except for the first and last fractions, 4 Gy), 2 fractions per day (b.i.d.), 5 days a week. Inclusion criteria for this analysis were: patients affected by squamous cell carcinoma with follow-up more than 6 months. Results: 20 patients with primary nasal vestibule cancer were treated with IRT from May 2012 to June 2019. We excluded 4 patients due to follow-up less than 6 months and 2 patients affected by basal cell carcinoma. In total, 14 consecutive previously untreated patients were considered for definitive analysis, median age was 67.5 (range, 51-83) years, median follow-up was 53 (range, 6-84) months. All patients followed the protocol except one, who received a total dose of 42 Gy in 12 fractions, 3 Gy per 6 fractions, and 4 Gy per 6 fractions. Local control at 12, 24, and 36 months was 85.7%. Overall survival at 12 months was 92.3%, at 24 months was 76.9%, and at 36 months was 69.2%. Staging system proposed by Wang was statistically significant on local control (LC), disease-free survival (DFS), disease-specific survival (DSS), and overall survival (OS). Excellent cosmetic results were observed. Conclusions: This study confirms that interventional radiotherapy could be considered as a definitive treatment in nasal vestibule cancer with excellent oncological and cosmetic outcomes.
Inglese
Tagliaferri, L., Carra, N., Lancellotta, V., Rizzo, D., Casa, C., Mattiucci, G., Parrilla, C., Fionda, B., Deodato, F., Cornacchione, P., Gambacorta, M. A., Paludetti, G., Valentini, V., Bussu, F., Interventional radiotherapy as exclusive treatment for primary nasal vestibule cancer: Single-institution experience, <>, 2020; 12 (5): 413-419. [doi:10.5114/jcb.2020.100373] [http://hdl.handle.net/10807/171559]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10807/171559
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 5
  • ???jsp.display-item.citation.isi??? 5
social impact